biostudies-literatureUnknown81(3)Benallegue N<h4>Importance</h4>Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.<h4>Objective</h4>To assess the real-world association of HET as an index treatment compared with MET with disease activity.<h4>Design, setting, and participants</h4>This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who recJAMA neurology273-282https://www.ebi.ac.uk/biostudies/studies/S-EPMC10862269biostudies-literatureHighly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.PMC10862269Labauge PKerbrat AHeinzlef ODebouverie MRollot FOlivier GMoreau TCasez OVukusic SFrancois CClaire GWiertlewski SZephir HCiron JThouvenot EPapeix CCabre PCeline LMaillart EClaire RBBerger EAl Khedr ABertrand APelletier JCorinne PClavelou PDefer GAlexandre PMagy LChantal NRomain MStankoff BJavier OPascal DAgnes FJean-Philippe NCasey RDe Seze JOFSEP (Observatoire Français de la Sclérose en Plaques) InvestigatorsInes DMikael CKarolina HBourre BNicolas CHaifa BNBenallegue NLebrun-Frenay CWahab ASolene MLaplaud DAEmmanuelle LPJean-Philippe CRuet AfalseHighly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.<h4>Importance</h4>Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.<h4>Objective</h4>To assess the real-world association of HET as an index treatment compared with MET with disease activity.<h4>Design, setting, and participants</h4>This was a retrospective cohort study conducted from January 1, 2010, to December 8, 2022, until the last recorded visit. The median follow-up was 5.8 years. A total of 36 French MS centers participated in the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort. Of the total participants in OFSEP, only treatment-naive children with relapsing-remitting POMS who rec2024-01-01T00:00:00Z2024 Mar2026-07-14T18:59:30.422Z2025-04-07T08:59:00.033ZS-EPMC108622693834579110.1001/jamaneurol.2023.5566